Hospital
Virtua - Memorial Hospital Burlington County, INC.
Virtua - Memorial Hospital Burlington County, INC. was paid $73.71M by Medicaid between Jan 2018 and Dec 2024, across 314 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoVIRTUA - MEMORIAL HOSPITAL BURLINGTON COUNTY, INC.
MOUNT HOLLY, NJ 08060
MOUNT HOLLY, NJ 08060
33aNPI1134125016assigned 06/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$73.71M
24GClaims1,140,871
24DCodes billed314
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#23 of 93
Median peer was paid$30.60M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 145,293 | $11.03M | |
| 2019 | 144,046 | $10.25M | |
| 2020 | 108,987 | $7.69M | |
| 2021 | 150,839 | $10.51M | |
| 2022 | 200,366 | $12.03M | |
| 2023 | 220,611 | $12.03M | |
| 2024incomplete | 170,729 | $10.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 57,056 | 51,725 | $24.94M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 31,064 | 29,240 | $10.19M |
| G0378 | Hospital observation service, per hour | 11% | 14,200 | 11,006 | $8.41M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 14,184 | 12,983 | $4.99M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 11,664 | 11,237 | $2.10M |
| OP278 | 2.7% | 1,346 | 1,129 | $1.96M | |
| 59025 | Fetal non-stress test | 1.9% | 9,499 | 5,556 | $1.38M |
| OP272 | 1.5% | 10,381 | 8,615 | $1.07M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 4,083 | 3,957 | $832K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.1% | 6,589 | 3,864 | $803K |
| OP370 | <1% | 6,865 | 5,752 | $654K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,922 | 2,842 | $651K |
302 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,170 | $548K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 28,918 | $533K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,924 | $514K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,777 | $508K |
| OP259 | <1% | 83,411 | $505K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,703 | $470K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 389 | $464K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,674 | $448K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,487 | $427K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,733 | $417K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,434 | $387K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 21,990 | $340K |
| 76830 | Ultrasound, transvaginal | <1% | 2,978 | $335K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,339 | $329K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,542 | $319K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,396 | $302K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,515 | $288K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 51,304 | $287K |
| 76818 | <1% | 1,626 | $285K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,732 | $285K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,326 | $284K |
| 76801 | <1% | 4,122 | $255K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,013 | $239K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 630 | $209K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 46,822 | $202K |
| OP258 | <1% | 32,966 | $200K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,844 | $196K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,121 | $190K |
| 95806 | <1% | 992 | $184K | |
| 97113 | <1% | 4,732 | $174K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,075 | $172K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,571 | $171K |
| 76813 | <1% | 1,161 | $156K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,437 | $151K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,268 | $146K |
| 76642 | <1% | 1,432 | $125K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 69,717 | $119K |
| 93971 | <1% | 1,602 | $115K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 955 | $113K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,811 | $108K |
| 93970 | <1% | 775 | $106K | |
| 97161 | <1% | 3,830 | $95K | |
| OP710 | <1% | 2,091 | $90K | |
| 80053 | Comprehensive metabolic panel | <1% | 14,849 | $88K |
| 73630 | <1% | 2,423 | $87K | |
| 76536 | <1% | 676 | $84K | |
| 93976 | <1% | 1,916 | $82K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 415 | $79K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 974 | $79K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 355 | $78K |
| 84484 | <1% | 13,409 | $77K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 199 | $76K |
| 82962 | <1% | 12,694 | $74K | |
| 74018 | <1% | 2,104 | $72K | |
| 73610 | <1% | 2,123 | $68K | |
| 73030 | <1% | 1,856 | $68K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,014 | $67K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,128 | $66K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 237 | $65K |
| 73564 | <1% | 1,618 | $65K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,466 | $62K |
| 72100 | <1% | 1,385 | $61K | |
| 77066 | Tomosynthesis, mammo | <1% | 464 | $61K |
| 73130 | <1% | 1,924 | $59K | |
| 80076 | <1% | 18,203 | $57K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,841 | $57K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,050 | $56K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,412 | $49K |
| 93017 | <1% | 712 | $45K | |
| 80306 | <1% | 6,437 | $43K | |
| 0240U | <1% | 1,000 | $43K | |
| 85027 | <1% | 12,466 | $42K | |
| 72110 | <1% | 352 | $42K | |
| 97162 | <1% | 1,483 | $41K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,412 | $41K |
| 76775 | <1% | 553 | $40K | |
| 86850 | <1% | 5,338 | $40K | |
| 94664 | <1% | 5,528 | $39K | |
| 80329 | <1% | 3,208 | $37K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,903 | $37K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,649 | $37K |
| 77065 | Tomosynthesis, mammo | <1% | 519 | $36K |
| 71250 | <1% | 257 | $35K | |
| 82248 | <1% | 9,031 | $34K | |
| 85730 | <1% | 12,656 | $34K | |
| 86900 | <1% | 6,494 | $33K | |
| 85610 | <1% | 13,701 | $32K | |
| 80061 | Lipid panel | <1% | 5,512 | $32K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,279 | $32K |
| 80320 | <1% | 4,420 | $31K | |
| 73560 | <1% | 810 | $31K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,212 | $31K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,257 | $31K |
| 81001 | <1% | 22,316 | $31K | |
| 83735 | <1% | 9,725 | $29K | |
| 83880 | <1% | 2,080 | $29K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,398 | $27K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 433 | $26K |
| 73110 | <1% | 731 | $26K | |
| 94760 | <1% | 7,484 | $25K | |
| 76942 | <1% | 438 | $25K | |
| 83690 | <1% | 10,695 | $25K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 38 | $23K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,841 | $22K |
| 87070 | <1% | 4,714 | $21K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 41 | $21K |
| 88342 | <1% | 959 | $20K | |
| 87040 | <1% | 2,943 | $20K | |
| 84702 | <1% | 3,265 | $20K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 307 | $20K |
| 70496 | <1% | 138 | $19K | |
| 97165 | <1% | 1,107 | $19K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 375 | $19K |
| 87581 | <1% | 1,073 | $18K | |
| 73502 | <1% | 715 | $18K | |
| 86703 | <1% | 1,512 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,941 | $18K |
| 87186 | <1% | 3,176 | $18K | |
| 59050 | <1% | 88 | $18K | |
| 87077 | <1% | 3,396 | $18K | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 85 | $17K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,783 | $17K |
| 70498 | <1% | 153 | $17K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 195 | $17K |
| 87486 | <1% | 994 | $17K | |
| 86901 | <1% | 6,515 | $16K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 26 | $16K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,470 | $15K |
| 87205 | <1% | 3,408 | $15K | |
| 87430 | <1% | 3,535 | $15K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 205 | $15K |
| 76770 | <1% | 73 | $15K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,458 | $14K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,287 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,638 | $14K |
| 86780 | <1% | 1,596 | $13K | |
| 87631 | <1% | 229 | $13K | |
| 84703 | <1% | 5,948 | $13K | |
| 74022 | <1% | 383 | $13K | |
| 90715 | <1% | 902 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 416 | $13K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 81 | $12K |
| 84100 | <1% | 3,876 | $11K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 610 | $11K |
| 70486 | <1% | 111 | $11K | |
| 85379 | <1% | 2,784 | $10K | |
| 72040 | <1% | 252 | $10K | |
| 81003 | <1% | 8,603 | $10K | |
| 83605 | <1% | 1,433 | $9K | |
| 73590 | <1% | 280 | $9K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,465 | $9K |
| 62323 | <1% | 14 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 897 | $8K |
| 95800 | <1% | 77 | $8K | |
| 85007 | <1% | 4,312 | $8K | |
| 82728 | <1% | 1,229 | $8K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,841 | $7K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,196 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,255 | $7K |
| 84439 | <1% | 1,525 | $7K | |
| 88307 | <1% | 175 | $7K | |
| 73090 | <1% | 193 | $6K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,619 | $6K |
| 86403 | <1% | 757 | $5K | |
| 82607 | <1% | 973 | $5K | |
| OP255 | <1% | 183 | $5K | |
| 94644 | <1% | 308 | $5K | |
| 88304 | <1% | 272 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 94 | $5K |
| 86787 | <1% | 400 | $5K | |
| 82247 | <1% | 1,867 | $5K | |
| 86140 | <1% | 2,561 | $5K | |
| 86803 | <1% | 485 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,323 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,234 | $4K |
| 88341 | <1% | 40 | $4K | |
| 97116 | <1% | 724 | $4K | |
| 93880 | <1% | 64 | $4K | |
| 70360 | <1% | 79 | $4K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,038 | $4K |
| 76870 | <1% | 49 | $4K | |
| 93798 | <1% | 98 | $4K | |
| 74019 | <1% | 88 | $3K | |
| OP229 | <1% | 65 | $3K | |
| 73140 | <1% | 108 | $3K | |
| 82550 | <1% | 1,374 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,316 | $3K |
| 94200 | <1% | 379 | $3K | |
| 76820 | <1% | 54 | $3K | |
| 83550 | <1% | 1,044 | $3K | |
| 72070 | <1% | 66 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,726 | $3K |
| 72050 | <1% | 24 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,944 | $2K |
| C1776 | Joint device (implantable) | <1% | 16 | $2K |
| 83020 | <1% | 334 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 232 | $2K |
| 77062 | <1% | 80 | $2K | |
| 87340 | <1% | 581 | $2K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 377 | $2K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 396 | $2K |
| 82746 | <1% | 396 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 310 | $2K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,603 | $2K |
| 73080 | <1% | 59 | $2K | |
| 85652 | <1% | 1,623 | $1K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 44 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 477 | $1K |
| J3490 | Unclassified drugs | <1% | 121 | $1K |
| 84156 | <1% | 970 | $1K | |
| 95816 | <1% | 14 | $1K | |
| 77336 | <1% | 23 | $1K | |
| 86762 | <1% | 454 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 59 | $1K |
| 82310 | <1% | 675 | $1K | |
| 71101 | <1% | 39 | $978.25 | |
| 82150 | <1% | 321 | $933.46 | |
| 85384 | <1% | 179 | $919.15 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 234 | $884.21 |
| OP720 | <1% | 19 | $866.43 | |
| 70491 | <1% | 14 | $846.43 | |
| 82947 | <1% | 595 | $787.58 | |
| 82565 | <1% | 602 | $786.08 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 871 | $715.21 |
| 82374 | <1% | 456 | $679.18 | |
| 90686 | <1% | 15 | $662.42 | |
| 84520 | <1% | 564 | $661.55 | |
| 84295 | <1% | 472 | $652.37 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 646 | $641.38 |
| 82043 | <1% | 553 | $616.55 | |
| 83970 | <1% | 67 | $575.33 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 121 | $570.63 |
| 82272 | <1% | 56 | $570.55 | |
| 82803 | <1% | 84 | $557.77 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 48 | $545.63 |
| 82435 | <1% | 469 | $528.42 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $528.31 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 16 | $502.17 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 75 | $496.64 |
| C1758 | Catheter, ureteral | <1% | 135 | $483.53 |
| 73060 | <1% | 12 | $467.16 | |
| 86481 | <1% | 15 | $459.04 | |
| 97164 | <1% | 12 | $434.26 | |
| 84153 | <1% | 63 | $433.87 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 98 | $414.45 |
| 99001 | <1% | 196 | $392.61 | |
| 36591 | <1% | 269 | $379.67 | |
| 77061 | <1% | 26 | $330.68 | |
| 97602 | <1% | 33 | $312.92 | |
| 84145 | <1% | 29 | $302.73 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 64 | $285.02 |
| 36416 | <1% | 164 | $276.81 | |
| 87147 | <1% | 116 | $272.96 | |
| 86039 | <1% | 50 | $260.66 | |
| 86710 | <1% | 62 | $251.38 | |
| 80365 | <1% | 23 | $242.55 | |
| 80361 | <1% | 23 | $242.55 | |
| 85045 | <1% | 159 | $242.30 | |
| 80367 | <1% | 23 | $225.06 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 251 | $224.65 |
| 84075 | <1% | 370 | $211.99 | |
| 84450 | <1% | 397 | $201.88 | |
| 94645 | <1% | 14 | $193.34 | |
| 80348 | <1% | 23 | $191.18 | |
| 81025 | <1% | 125 | $187.46 | |
| 80354 | <1% | 23 | $181.28 | |
| 80356 | <1% | 23 | $181.28 | |
| 80358 | <1% | 23 | $181.28 | |
| 84460 | <1% | 384 | $179.36 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 132 | $170.57 |
| 83615 | <1% | 101 | $166.61 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 170 | $143.22 |
| 86618 | <1% | 30 | $138.01 | |
| 84155 | <1% | 382 | $123.50 | |
| 99152 | <1% | 15 | $120.89 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 73 | $119.77 |
| 87641 | <1% | 28 | $113.27 | |
| 82040 | <1% | 393 | $108.09 | |
| 80164 | <1% | 16 | $96.75 | |
| 80074 | <1% | 16 | $96.64 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 14 | $96.46 |
| 85046 | <1% | 31 | $90.61 | |
| 87210 | <1% | 104 | $83.78 | |
| 84550 | <1% | 59 | $74.44 | |
| 87640 | <1% | 29 | $62.25 | |
| 80177 | <1% | 27 | $60.17 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 14 | $60.04 |
| 85651 | <1% | 29 | $57.12 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23 | $49.11 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 19 | $47.32 |
| 86592 | <1% | 15 | $38.10 | |
| 82950 | <1% | 12 | $34.20 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 25 | $26.31 |
| 87088 | <1% | 15 | $14.77 | |
| 86706 | <1% | 12 | $12.00 | |
| 82465 | <1% | 30 | $11.52 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 253 | $11.28 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 12 | $10.03 |
| J7643 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram | <1% | 182 | $8.42 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 27 | $6.13 |
| 86308 | <1% | 14 | $6.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 86 | $2.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOWE, GERRY (VP FOR FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Virtua - West Jersey Health System, INC. | Voorhees, NJ | $255.73M |
| Virtua - West Jersey Health System, INC. | Marlton, NJ | $2.39M |
| Virtua - Memorial Hospital of Burlington County, INC. | Mount Laurel, NJ | $300K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.